Lipohypertrophy 发表于 2025-3-26 22:07:14
http://reply.papertrans.cn/95/9438/943784/943784_31.pngGratulate 发表于 2025-3-27 01:26:31
IABP/ECMO, and safety profile. Recently, the strategies are changing based on large clinical trials. The use of veno-arterial extracorporeal membrane oxygenation (VA-ECMO) for refractory cardiogenic shock is rapidly increasing, with the improvement of device technology and practical management. VA-ECMO can ac易怒 发表于 2025-3-27 07:57:00
Impella,entricle to the ascending aorta, improving systemic circulation and end-organ dysfunction and unloading left ventricle in patients with cardiogenic shock. Impella has not shown a significant survival benefit in patients with cardiogenic shock compared with conventional intra-aortic balloon pumping i支形吊灯 发表于 2025-3-27 09:56:20
MitraClip,ve repair or replacement might be effective in some of the cases, but it has been challenging particularly for the high-risk cases. Recently, percutaneous edge-to-edge mitral valve repair using the MitraClip system, which enables us to approach the mitral valve at relatively low risk, has been develharmony 发表于 2025-3-27 15:31:41
http://reply.papertrans.cn/95/9438/943784/943784_35.png裁决 发表于 2025-3-27 19:50:34
http://reply.papertrans.cn/95/9438/943784/943784_36.png感情脆弱 发表于 2025-3-27 23:57:58
http://reply.papertrans.cn/95/9438/943784/943784_37.png披肩 发表于 2025-3-28 04:02:11
Regenerative Medicine for Heart Failure: A Comprehensive Overview of Clinical Studies, Current Chaletal myoblasts in HF, a number of preclinical and clinical studies have been conducted, which support the ability of various stem cell populations to improve cardiac function and reduce the infarct size in HF. However, it is still too early in this new era of regenerative cell therapy as the novel mPrologue 发表于 2025-3-28 10:08:06
http://reply.papertrans.cn/95/9438/943784/943784_39.png领巾 发表于 2025-3-28 10:36:42
http://reply.papertrans.cn/95/9438/943784/943784_40.png